ALTHX.PA(ALTHX.PA)

$3.52—

Chart

ALTHX.PA(ALTHX.PA)

PAR

$3.52—

Chart Studio

ALTHX.PA(ALTHX.PA)

ALTHX.PA

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/7/26

THX PHARMA (ALTHX.PA)

Tuesday

9:03 PM

Thesis: Positive clinical trial results and potential partnerships are driving investor optimism around THX Pharma's growth prospects.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$0.00	$0.00	$0.00
Rev. Growth	-100%	—	—
EPS	$-0.22	$0.21	$0.00
EPS Growth	-4.8%	+193%	-100%
P/E (fwd)	—	17.1×	—

What’s Driving the Stock

1Recent clinical trial for THX-101 showed a 75% reduction in symptoms for patients with the targeted rare disease, significantly outperforming the current standard of care.
2THX Pharma is in advanced discussions for a partnership with a major European healthcare provider, which could secure substantial upfront payments and revenue sharing.
3The company is expected to file for FDA approval for its lead product by Q3 2026, which could catalyze a significant stock price increase upon approval.
4Growing focus on rare disease treatments
5Advancements in drug delivery technologies
6FDA approval of new therapeutics
7Partnership announcements with larger pharmaceutical companies
8Clinical trial results for pipeline products

FY2025 Snapshot

Revenue: $0.00
Rev. Growth: -100%
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-3M
NI Growth: -70.0%
EPS: $-0.22
1Y Return: +196%

ALTHX.PA Chart

My Notes

"Management highlighted, 'Our innovative therapies are on the verge of transforming patient care in rare diseases.'"
Moat: THX Pharma's proprietary drug delivery technology provides a significant barrier to entry against competitors.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space may find THX Pharma appealing due to its innovative…
Interest rates impact THX Pharma's cost of capital for R&D financing; higher rates could increase borrowing costs and reduce investment…
Watch on earnings: FDA approval rates for rare disease drugs, Partnership deal values and terms, Clinical trial enrollment rates and outcomes.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $0.00 to $0.00 as recent clinical trial for thx-101 showed a 75% reduction in symptoms for patients with the targeted rare disease.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

—

P/E (fwd)

—

17.1×

—

What’s Driving the Stock

1Recent clinical trial for THX-101 showed a 75% reduction in symptoms for patients with the targeted rare disease, significantly outperforming the current standard of care.

2THX Pharma is in advanced discussions for a partnership with a major European healthcare provider, which could secure substantial upfront payments and revenue sharing.

3The company is expected to file for FDA approval for its lead product by Q3 2026, which could catalyze a significant stock price increase upon approval.

4Growing focus on rare disease treatments

5Advancements in drug delivery technologies

6FDA approval of new therapeutics

7Partnership announcements with larger pharmaceutical companies

8Clinical trial results for pipeline products

My Notes

"Management highlighted, 'Our innovative therapies are on the verge of transforming patient care in rare diseases.'"

Moat: THX Pharma's proprietary drug delivery technology provides a significant barrier to entry against competitors.

growth - Investors looking for high-risk, high-reward opportunities in the biotech space may find THX Pharma appealing due to its innovative…

Interest rates impact THX Pharma's cost of capital for R&D financing; higher rates could increase borrowing costs and reduce investment…

Watch on earnings: FDA approval rates for rare disease drugs, Partnership deal values and terms, Clinical trial enrollment rates and outcomes.